INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Pomerantz LLP is investigating potential securities fraud claims against CVRx, Inc. (NASDAQ: CVRX) on behalf of its investors. The investigation follows two significant stock price drops in 2025 after the company announced weaker-than-expected quarterly results and lowered its revenue guidance due to salesforce issues. Investors affected by these events are encouraged to contact the law firm.
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Glancy Prongay Wolke & Rotter LLP has announced a securities fraud investigation into CVRx, Inc. (CVRX) following significant stock price drops due to disappointing revenue figures and issues with salesforce integration. The law firm is urging shareholders who experienced losses to contact them to inquire about recovering their investments. The investigation focuses on CVRx's potential violations of federal securities laws after multiple announcements of lower-than-anticipated revenue and challenges with new sales representatives.
CVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
The Law Offices of Howard G. Smith are investigating CVRx, Inc. (CVRX) on behalf of investors alleging possible violations of federal securities laws. The investigation stems from significant stock price declines following several disappointing financial announcements by CVRx in April 2025, May 2025, and February 2026, primarily related to sales force issues and revised revenue guidance. Shareholders who suffered losses are encouraged to contact the firm for potential legal claims.
Cantor Fitzgerald Upgrades CVRx (NASDAQ:CVRX) to Strong-Buy
Cantor Fitzgerald has upgraded CVRx (NASDAQ:CVRX) to a "strong-buy" rating, indicating increased analyst confidence despite the stock's current "Moderate Buy" consensus. CVRx shares were trading down approximately 4.2% after opening at $4.74, significantly below its 50- and 200-day moving averages. The company recently reported a Q4 EPS miss and remains unprofitable, with institutional investors showing mixed activity, including GSK plc acquiring a new stake.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Pomerantz LLP is investigating potential securities fraud claims against CVRx, Inc. on behalf of investors. The investigation follows significant drops in CVRx's stock price after the company announced weaker-than-expected Q1 2025 results and subsequently lowered full-year revenue guidance, attributing the issues to new sales representatives and recent salesforce changes. Investors who suffered losses are encouraged to contact the law firm for information about joining a class action.
Short Interest in CVRx, Inc. (NASDAQ:CVRX) Increases By 23.4%
Short interest in CVRx, Inc. (NASDAQ:CVRX) rose significantly by 23.4% in January, reaching 1,642,563 shares, which accounts for about 7.7% of its float. This increase results in a days-to-cover ratio of 3.4 days based on average daily trading volume. The company recently reported a wider-than-expected quarterly EPS loss of ($0.46) despite slightly exceeding revenue forecasts, and institutional investors currently hold roughly 75% of CVRx stock.
Analysts Are Updating Their CVRx, Inc. (NASDAQ:CVRX) Estimates After Its Full-Year Results
CVRx, Inc. (NASDAQ:CVRX) shares dropped 24% following its latest full-year results, with revenues meeting forecasts but statutory losses per share slightly increasing from previous expectations. Analysts are now forecasting an increase in revenues for 2026 to US$64.9m, a 15% improvement, though losses are expected to remain steady at US$2.03 per share. Despite the adjusted loss forecasts, the consensus price target remains unchanged, suggesting analysts do not anticipate a long-term impact on the company's valuation.
Analysts Are Updating Their CVRx, Inc. (NASDAQ:CVRX) Estimates After Its Full-Year Results
CVRx, Inc. recently saw its shares plunge 24% after releasing full-year results, with revenues meeting forecasts but statutory losses slightly higher than expected. Analysts are now forecasting revenues of US$64.9m for 2026, a 15% increase, while losses are projected to remain steady at US$2.03 per share, a modest increase from previous expectations. Despite the higher forecast losses, the consensus price target remained at US$11.17, indicating analysts believe this will not significantly impact the company's long-term valuation, and they anticipate CVRx will grow faster than the wider industry.
Piper Sandler Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $12
Piper Sandler analyst Matthew O'Brien has reaffirmed a Buy rating for CVRx Inc (CVRX.US), maintaining a target price of $12. According to TipRanks, O'Brien has a 38.1% success rate and an average return of -6.8% over the past year. TipRanks provides independent analysis of financial analysts' recommendations, including success rates and average returns, for informational purposes only.
CVRx Earnings Call: Investing Heavily for Future Growth
CVRx Inc. (CVRX) Q4 earnings call revealed a strategy of heavy investment for future growth, prioritizing a larger commercial franchise over short-term earnings. While the company reported rising revenues, improved gross margins, and significant progress in reimbursement and clinical trials, it also acknowledged increased net losses and operating expenses due to these strategic investments. The future hinges on sustained procedural growth, careful cash management, and the successful execution of the BENEFIT HF trial to realize long-term financial benefits.
Canaccord Genuity lowers CVRx stock price target to $10 on sector multiple decline
Canaccord Genuity has reduced its price target for CVRx Inc (NASDAQ:CVRX) from $11.00 to $10.00, while maintaining a Buy rating, citing declining sector multiples. Despite the stock trading below its fair value and the company exceeding Q4 2025 revenue expectations, CVRx is projected not to be profitable this year. The firm anticipates future growth driven by improved salesforce productivity, CMS coverage approval for a trial, and CPT codes reducing reimbursement friction for its Barostim therapy.
CVRx highlights revenue growth in Q4, increased momentum going forward
CVRx reported $16 million in revenue for Q4 2025, a 4% increase year-over-year, with total 2025 revenue reaching $56.7 million, up 10% from 2024. The company is heading into 2026 with increased momentum due to new Category 1 CPT codes for its Barostim device and the initiation of a new clinical trial, BENEFIT-HF, aiming to expand eligibility for heart failure therapy. CVRx's CEO, Kevin Hykes, expressed confidence that these developments will support accelerated growth and make Barostim therapy more accessible.
Canaccord Genuity lowers CVRx stock price target to $10 on sector multiple decline
Canaccord Genuity has lowered its price target for CVRx Inc. (NASDAQ: CVRX) to $10 from $11, while maintaining a Buy rating. The adjustment comes despite CVRx exceeding revenue expectations in Q4 2025 and having positive long-term prospects like expanded market access for its Barostim therapy and improved reimbursement, though analysts do not anticipate profitability this year. The price target reduction is primarily due to declining multiples within the small-cap medical technology sector.
CVRx, Inc. SEC 10-K Report
CVRx, Inc. has released its annual 10-K report, detailing a 10% revenue increase to $56.7 million and an improved net loss of $(53.3) million for the year. The report highlights the success of its flagship product, Barostim, and the company's strategies for market expansion, R&D, and managing operational and regulatory risks. CVRx plans to continue investing in commercialization and R&D while actively managing capital and facing ongoing net losses in the short term.
Responsive Playbooks and the CVRX Inflection
This article provides an AI-generated analysis of Cvrx Inc. (NASDAQ: CVRX), highlighting weak sentiment across all horizons and a potential short bias. It outlines three distinct trading strategies: position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels. The analysis also emphasizes an exceptional risk-reward setup targeting a significant gain with minimal risk.
CVRX: Revenue and margin growth set the stage for accelerated expansion with new reimbursement and clinical trial catalysts
CVRx, Inc. (CVRX) reported growth in revenue and improved margins for Q4 and full-year 2025, attributed to sales force expansion and strategic investments. The company anticipates accelerated growth and market expansion in 2026 due to the transition to Category I CPT codes and the initiation of the BENEFIT-HF clinical trial, positioning CVRX for future expansion.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Pomerantz LLP is investigating potential securities fraud claims against CVRx, Inc. (CVRX) on behalf of investors. This investigation follows significant drops in CVRx's stock price after the company announced weaker-than-expected preliminary first-quarter results in April 2025 and subsequently lowered its full-year revenue guidance in May 2025, attributing issues to salesforce changes. Investors affected by these events are encouraged to contact the law firm.
Earnings call transcript: CVRx Q4 2025 sees stock surge despite earnings miss
CVRx Inc. (CVRX) reported Q4 2025 earnings with an EPS miss of -$0.46 against a forecast of -$0.44, but revenue surpassed expectations at $16 million. Despite the EPS miss, the stock surged 12.01% after hours due to positive investor sentiment driven by revenue growth and an optimistic 2026 outlook of 11-18% growth. The company's future strategy includes expanding sales territories, refining sales approach, and the BENEFIT-HF trial, which is expected to triple its addressable market and boost market penetration.
CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
CVRx, Inc. announced its financial and operating results for the fourth quarter and full year of 2025, reporting total revenue of $16.0 million for Q4 2025 and $56.7 million for the full year, representing increases of 4% and 10% respectively over the prior year. The company saw growth in active implanting centers and sales territories, initiated the BENEFIT-HF trial, and anticipates continued revenue growth for 2026. Despite increased revenue, the company reported net losses of $11.9 million for Q4 and $53.3 million for the full year 2025.
CVRx: Fourth Quarter Financial Highlights
CVRx Inc. reported a net loss of $11.9 million for the fourth quarter, with a loss of $0.46 per share, missing analyst expectations of $0.42 per share. The medical technology firm generated $16 million in revenue for the quarter. For the full year, CVRx posted a total loss of $53.3 million ($2.04 per share) on $56.7 million in revenue and provided revenue guidance for the upcoming quarter and full year.
CVRx: Q4 Earnings Snapshot
CVRx Inc. reported a Q4 loss of $11.9 million, or 46 cents per share, missing analyst expectations. The medical device company posted revenue of $16 million for the quarter and a full-year loss of $53.3 million on $56.7 million in revenue. CVRx provided future guidance, expecting Q1 revenue between $13.7 million and $14.7 million, and full-year revenue ranging from $63 million to $67 million.
CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
CVRx, Inc. announced its financial and operating results for the fourth quarter and full year 2025, reporting total revenue of $16.0 million and $56.7 million, respectively, marking increases over the prior year. The company saw growth in active implanting centers and initiated the BENEFIT-HF trial, aiming to triple its addressable market for heart failure patients. CVRx also updated its term loan agreement and provided financial guidance for the full year and first quarter of 2026.
CVRx (CVRX) Q4 2025 Earnings Call Transcript
CVRx reported Q4 2025 revenue of $16 million, a 4% increase, with gross margin improving to 86%. Despite a net loss of $11.9 million, the company showed progress in U.S. and European adoption, increased active implanting centers, and expanded sales territories. CVRx initiated the landmark BENEFIT HF trial, which could significantly enlarge its addressable market, and implemented Category I CPT codes to enhance reimbursement predictability and reduce prior authorization denials.
CVRX INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving CVRx Inc.
Kirby McInerney LLP is investigating potential federal securities law violations by CVRx Inc. and its senior management. This comes after CVRx announced weaker-than-expected preliminary first-quarter 2025 results and subsequently lowered its full-year revenue guidance, citing issues with newer sales representatives and significant salesforce changes. These announcements led to substantial declines in CVRx's stock price, prompting the law firm's investigation.
CVRx, Inc. (NASDAQ:CVRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Seven brokerages have issued a consensus "Moderate Buy" rating for CVRx, Inc. (NASDAQ:CVRX), with an average 12-month price target of $11.40. Institutional investors, including Vanguard and Balyasny, collectively own about 75.27% of the company, with several increasing their stakes. CVRx, a clinical-stage medical device company, is trading around $6.55 with a negative P/E ratio, reflecting its developmental status and focus on a neuromodulation platform for cardiovascular disease.
CVRx showcases Barostim integration at heart failure program
CVRx recently showcased the integration of its Barostim therapy at the #UCARS26 event, bringing together medical professionals Dr. Shelley Hall and Dr. Bhimaraj. The discussion focused on how Barostim, an innovative approach to managing heart conditions, can be effectively incorporated into existing frameworks to improve patient outcomes for heart failure patients. This highlights CVRx's commitment to advancing treatment options in cardiology.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Pomerantz LLP is investigating CVRx, Inc. (CVRX) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows significant drops in CVRx's stock price in April and May 2025 after the company announced weaker-than-expected preliminary and first-quarter results and lowered its full-year revenue guidance, attributing the issues to new sales representatives being in early development and recent salesforce changes. Investors affected by these events are encouraged to contact Pomerantz LLP.
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
CVRx, Inc. announced it will release its fourth quarter 2025 financial and operating results after market close on Thursday, February 12, 2026. The company will host a conference call on the same day at 4:30 p.m. Eastern Time to discuss the results. A live webcast and dial-in details are provided for investors and interested parties.
CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating
Bragar Eagel & Squire, P.C. is investigating potential federal securities law violations by CVRx Inc. on behalf of its stockholders. The investigation follows significant drops in CVRx's stock price after the company announced weaker than expected preliminary Q1 2025 results and subsequently lowered its full-year revenue guidance, attributing issues to salesforce changes. Investors who suffered losses or have information are encouraged to contact the firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Pomerantz LLP is investigating CVRx, Inc. (NASDAQ: CVRX) on behalf of investors for potential securities fraud and unlawful business practices. The investigation follows significant drops in CVRx's stock price in April and May 2025, after the company announced weaker than expected preliminary Q1 results and lowered its full-year revenue guidance, attributing the issues to newly hired sales representatives. Investors affected by these events are encouraged to contact Pomerantz LLP.
CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating
Bragar Eagel & Squire, P.C., a stockholder rights law firm, is investigating potential claims against CVRx Inc. on behalf of CVRx stockholders. This investigation follows significant drops in CVRx's stock price after the company announced weaker-than-expected preliminary first-quarter results in April 2025 and subsequently lowered full-year revenue guidance in May 2025, attributing the issues to new sales representatives and salesforce changes. Investors who suffered losses are encouraged to contact the firm to discuss their legal options.
CVRx INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Kirby McInerney LLP has announced an investigation into potential securities fraud against CVRx Inc. following two significant drops in stock price. The investigation centers on statements made by CVRx's CEO regarding weaker-than-expected preliminary first-quarter results and subsequent lowered full-year revenue guidance, which were attributed to issues with new sales representatives and more significant salesforce changes than anticipated. Investors who purchased CVRx securities may contact the firm to learn more about their rights.
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
CVRx, Inc. announced its plan to release fourth quarter 2025 financial and operating results after market close on Thursday, February 12, 2026. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. A live webcast will be available on CVRx's investor relations website, and dial-in details are provided for teleconference participation.
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
CVRx, Inc. announced that it will release its fourth quarter 2025 financial and operating results after market close on Thursday, February 12, 2026. The company will also host a conference call on the same day at 4:30 p.m. ET to discuss the results. Attendees can access the webcast online or dial in via telephone.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Pomerantz LLP is investigating CVRx, Inc. (NASDAQ: CVRX) on behalf of investors for potential securities fraud and unlawful business practices. This investigation follows significant drops in CVRx's stock price after the company announced weaker-than-expected preliminary and full-year revenue guidance in April and May 2025, attributing the issues to inexperienced sales representatives and unexpected challenges with recent salesforce changes. Investors affected by these events are encouraged to contact Pomerantz LLP.
CVRx announces initiation of BENEFIT-HF heart failure trial of Barostim device in “significantly expanded population”
CVRx has initiated the BENEFIT-HF clinical trial to evaluate its Barostim neuromodulation device in an expanded heart failure population. This randomized study, supported by CMS, will enroll 2,500 patients across 150 centers in the USA and Germany, making it one of the largest therapeutic cardiac device trials for heart failure. The trial aims to potentially triple the indicated patient population for Barostim by including patients with a left ventricular ejection fraction (LVEF) <50% and NT-proBNP levels <5,000pg/mL, compared to the current, more restrictive indications.
CVRx supports MU Health with first Barostim implant
CVRx, a medical therapies company, has partnered with MU Health for the successful first implant of its Barostim device, aimed at treating heart failure symptoms. This achievement, led by Dr. Semaan Kobrossi and Dr. Steven Cheung, signifies a significant advance in bioelectronic medicine and underscores the importance of collaboration in improving healthcare outcomes for heart failure patients.
The Truth About CVRx Inc: Wall Street’s Sleeping Giant You’re Not Watching (Yet)
CVRx Inc (CVRX) is presented as a "sleeping giant" in the medtech sector, focusing on an implantable device called Barostim for resistant hypertension and heart failure. The article highlights its potential as a game-changer for patients with limited options, emphasizing its high-risk, high-reward nature due to its small market cap and the slow adoption process typical for medical devices. Investors are advised to exercise caution and conduct thorough due diligence before considering investment.
CVRx Kicks Off One Of The Largest Heart Device Trials In History
CVRx, Inc. (NASDAQ: CVRX) has initiated the BENEFIT-HF clinical trial, a large-scale study evaluating its Barostim device for heart failure patients, which could triple the company's total addressable market if successful. The trial, supported by CMS Category B IDE coverage, will randomize 2,500 patients and focus on reducing all-cause mortality and heart failure decompensation events, with enrollment expected to begin in the first half of 2026. William Blair maintains an Outperform rating on CVRX, highlighting the significant market expansion potential and increased attention for Barostim within the cardiology community.
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Maravai Lifesciences Holdings (MRVI) and CVRx (CVRX)
The article highlights bullish analyst sentiments for three healthcare companies: Abbott Laboratories (ABT), Maravai Lifesciences Holdings (MRVI), and CVRx (CVRX). Jefferies reiterated a Buy rating for Abbott with a $145 price target, while Craig-Hallum maintained Buy ratings for both Maravai Lifesciences and CVRx, with price targets of $4.25 and $12.67 respectively. All three companies received a "Strong Buy" consensus rating from analysts.
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Maravai Lifesciences Holdings (MRVI) and CVRx (CVRX)
Three analysts recently issued bullish sentiments on healthcare companies Abbott Laboratories (ABT), Maravai Lifesciences Holdings (MRVI), and CVRx (CVRX). Jefferies reiterated a Buy rating on Abbott Laboratories with a $145 price target, while Craig-Hallum maintained Buy ratings on both Maravai Lifesciences Holdings and CVRx, setting price targets of $4.25 and $12.67 respectively. All three companies currently hold a "Strong Buy" analyst consensus.
CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
CVRx, Inc. has announced the initiation of the BENEFIT-HF clinical trial, a large-scale randomized study evaluating its Barostim device for heart failure patients. This trial aims to expand the indicated patient population for Barostim by approximately three times, targeting patients with less severe left ventricular ejection fraction and higher NT-proBNP levels than the current indication. Supported by CMS Category B IDE coverage, the study will enroll 2,500 patients across 150 centers in the U.S. and Germany, focusing on composite outcomes of all-cause mortality and heart failure decompensation.
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating
Craig-Hallum analyst Chase Knickerbocker has reiterated a "buy" rating for CVRx Inc (CVRX.US). The analyst has a notable success rate of 61.8% and an average return of 38.4% over the past year, according to TipRanks data. This information is intended for informational purposes only and does not constitute investment advice.
CVRx’s stock up as heart failure device to be trialled in expanded patient group
CVRx's stock rose significantly after the company announced an expanded clinical trial for its Barostim heart failure device. The BENEFIT-HF trial will investigate the device in a larger patient population, potentially tripling its indicated use if successful. This expansion could significantly broaden access to the neuromodulation-based heart failure management solution, leading to investor enthusiasm.
CVRx’s stock up as heart failure device to be trialled in expanded patient group
CVRx's stock rose significantly after the company announced its Barostim heart failure device would be trialled in an expanded patient population through the BENEFIT-HF study. If successful, this trial could triple the indicated patient population for Barostim, broadening access to this neuromodulation-based therapy. The device is already approved in the US and Europe for specific heart failure patient groups and aims to improve symptoms by rebalancing the autonomic nervous system.
CVRx launches major heart failure trial to expand Barostim therapy reach
CVRx, Inc. (NASDAQ:CVRX) has announced the initiation of its BENEFIT-HF clinical trial, a large-scale study evaluating its Barostim therapy in an expanded heart failure patient population. The trial aims to enroll 2,500 patients across 150 centers in the US and Germany, potentially tripling the indicated patient population for Barostim if successful. This strategic move, along with recent positive financial outlooks and CPT code approvals, highlights CVRx's advancements in the healthcare market.
CVRx Initiates BENEFIT-HF Trial; Q4 Financial Report Coming Soon
CVRx, Inc. has launched the BENEFIT-HF clinical trial to assess its FDA-approved Barostim device in a wider heart failure patient group, aiming to triple the treatable population if successful. The trial will enroll 2,500 patients across the U.S. and Germany, with CMS approval for coverage. CVRx also anticipates releasing its Q4 and full-year 2025 financial results in February, projecting continued revenue growth for 2025 and 2026.
CVRx launches major heart failure trial to expand Barostim therapy reach
CVRx, Inc. (NASDAQ:CVRX) announced the initiation of its BENEFIT-HF clinical trial, a large-scale study evaluating its Barostim therapy for an expanded heart failure patient population. This randomized trial will enroll 2,500 patients aimed at potentially tripling the indicated patient population for Barostim by broadening current usage criteria. The company, despite being unprofitable, has shown strong revenue growth and is considered slightly undervalued based on Fair Value estimates.
CVRx stock rises after announcing major heart failure clinical trial
CVRx Inc. (NASDAQ:CVRX) announced a major clinical trial, BENEFIT-HF, to evaluate its Barostim neuromodulation therapy for a broader heart failure population. This trial, expected to be one of the largest therapeutic cardiac device trials for heart failure, involves 2,500 patients and could significantly expand the patient population for Barostim. Following this announcement, CVRx stock rose 2.9% in after-hours trading.
CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
CVRx, Inc. has announced the initiation of the BENEFIT-HF clinical trial, a large-scale study evaluating its Barostim device in an expanded heart failure population. The trial, supported by CMS Category B IDE coverage, aims to enroll 2,500 patients across 150 centers to assess the device's impact on all-cause mortality and heart failure decompensation. If successful, the study could significantly broaden the Barostim's market by three times, making it accessible to a wider range of heart failure patients.
